{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:11:42Z","timestamp":1778739102338,"version":"3.51.4"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Left ventricular thrombus (LVT) is associated with substantial risk of embolism and mortality. Given the growing use of direct oral anticoagulants for LVT and evolving evidence, we conducted an updated, comprehensive systematic review and meta-analysis comparing their effectiveness and safety with vitamin K antagonists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed\/MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from inception through the most recent search date for randomized controlled trials and observational studies comparing DOACs with VKAs in adults with imaging-confirmed LVT. Outcomes of interest included LVT resolution, systemic embolic events, all-cause mortality, bleeding events, and composite clinical outcomes. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models. Statistical heterogeneity was assessed using the I\u00b2 statistic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 29 studies, comprising randomized controlled trials and observational cohorts, were included. Compared with VKAs, DOAC therapy was associated with a numerically higher likelihood of LVT resolution, although this did not reach statistical significance (RR 1.06, 95% CI 0.98\u20131.14; I\u00b2\u2009=\u200948.2%). There was no significant difference in the risk of systemic embolic events between DOACs and VKAs (RR 0.89, 95% CI 0.78\u20131.03; I\u00b2\u2009=\u20095.5%). DOAC use was associated with a lower risk of all-cause mortality (RR 0.84, 95% CI 0.64\u20131.09; I\u00b2\u2009=\u20095.5%); however, this finding was primarily driven by observational data. DOACs were also associated with a lower risk of bleeding events (RR 0.86, 95% CI 0.72\u20131.03; I\u00b2\u2009=\u200916.4%), although this did not reach statistical significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this updated meta-analysis, DOACs were associated with a numerically higher rate of LVT resolution, although this did not reach statistical significance, and with lower rates of bleeding compared with VKAs, without an increased risk of systemic embolic events. Although a lower risk of all-cause mortality was observed, this finding was primarily driven by observational studies and should be interpreted with caution. These findings support DOACs as a reasonable and potentially safer alternative to VKAs for the management of LVT, while emphasizing the need for adequately powered randomized trials to confirm optimal anticoagulation strategies in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251181379<\/jats:ext-link>\n                      , PROSPERO CRD420251181379.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1814694","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:33:39Z","timestamp":1778736819000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Direct oral anticoagulants versus warfarin for left ventricular thrombus: an updated systematic review and meta-analysis of randomized and observational studies"],"prefix":"10.3389","volume":"13","author":[{"given":"Lama","family":"Alfehaid","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"Pharmaceutical Care Department, King Abdulaziz Medical City","place":["Riyadh, Saudi Arabia"]},{"name":"Department of Pharmacy Practice, King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinan","family":"Alhuwayshil","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoug","family":"Almousa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehsan","family":"Habeeb","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, Taibah University","place":["Madinah, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majed S.","family":"Al Yami","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"Pharmaceutical Care Department, King Abdulaziz Medical City","place":["Riyadh, Saudi Arabia"]},{"name":"Department of Pharmacy Practice, King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1161\/CIR.0000000000001092","article-title":"Management of patients at risk for and with left ventricular thrombus: a scientific statement from the American Heart Association","volume":"146","author":"Levine","year":"2022","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1136\/heartjnl-2012-301962","article-title":"Left ventricular thrombus formation after acute myocardial infarction","volume":"98","author":"Delewi","year":"2012","journal-title":"Heart"},{"key":"B3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12959-024-00632-5","article-title":"Evaluation of the efficacy and safety of rivaroxaban compared to warfarin in patients with left ventricular apical thrombus: a randomized clinical trial","volume":"22","author":"Mansouri","year":"2024","journal-title":"Thromb J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.jacc.2022.01.011","article-title":"Left ventricular thrombus following acute myocardial infarction","volume":"79","author":"Camaj","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Collet","year":"2023","journal-title":"Eur Heart J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"520","DOI":"10.21037\/atm-20-7839","article-title":"Management of left ventricular thrombus: a narrative review","volume":"9","author":"Cruz Rodriguez","year":"2021","journal-title":"Ann Transl Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e771","DOI":"10.1161\/CIR.0000000000001309","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"B9","year":"2023"},{"key":"B10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomized trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"key":"B12","year":"2025"},{"key":"B13","doi-asserted-by":"publisher","first-page":"101978","DOI":"10.1016\/j.jacadv.2025.101978","article-title":"Rivaroxaban vs warfarin in acute left ventricular thrombus following myocardial infarction","volume":"4","author":"Shah","year":"2025","journal-title":"JACC Advances"},{"key":"B14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.cjco.2022.11.011","article-title":"Apixaban in patients with post-myocardial infarction left ventricular thrombus: a randomized clinical trial","volume":"5","author":"Youssef","year":"2023","journal-title":"CJC Open"},{"key":"B15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4244\/EIJ-D-24-00527","article-title":"Direct oral anticoagulants or warfarin in patients with left ventricular thrombus after ST-elevation myocardial infarction","volume":"21","author":"Jenab","year":"2025","journal-title":"EuroIntervention"},{"key":"B16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12959-020-00242-x","article-title":"Direct oral anticoagulant use in left ventricular thrombus","volume":"18","author":"Ali","year":"2022","journal-title":"Thromb J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.jacc.2021.01.049","article-title":"Comparative study of oral anticoagulation in left ventricular thrombi (No-LVT trial)","volume":"77","author":"Abdelnabi","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4103\/JCPC.JCPC_41_20","article-title":"Apixaban versus warfarin in patients with left ventricular thrombus: a pilot prospective randomized outcome blinded study investigating size reduction or resolution of left ventricular thrombus","volume":"9","author":"Isa","year":"2021","journal-title":"Clinical Prevention in Cardiology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/jamacardio.2020.0652","article-title":"Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi","volume":"5","author":"Robinson","year":"2020","journal-title":"JAMA Cardiology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1002\/ehf2.12718","article-title":"Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus","volume":"7","author":"Iqbal","year":"2020","journal-title":"ESC Heart Failure"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.amjmed.2020.05.025","article-title":"Treatment of left ventricular thrombus with direct oral anticoagulants","volume":"133","author":"Guddeti","year":"2020","journal-title":"Am J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40261-020-00898-3","article-title":"Management of left ventricular thrombi with direct oral anticoagulants","volume":"40","author":"Daher","year":"2020","journal-title":"Clin Drug Investig"},{"key":"B23","doi-asserted-by":"publisher","first-page":"9427","DOI":"10.21037\/apm-21-1683","article-title":"Direct oral anticoagulants versus vitamin K antagonists for patients with left ventricular thrombus","volume":"10","author":"Xu","year":"2021","journal-title":"Ann Palliat Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s11739-021-02788-8","article-title":"Direct oral anticoagulants versus warfarin for the treatment of left ventricular thrombosis","volume":"16","author":"Mihm","year":"2021","journal-title":"Intern Emerg Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/ehjcvp\/pvaa096","article-title":"The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction","volume":"7","author":"Jones","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B26","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1177\/1060028020975111","article-title":"Direct oral anticoagulants versus warfarin in the treatment of left ventricular thrombus","volume":"55","author":"Willeford","year":"2021","journal-title":"Ann Pharmacother"},{"key":"B27","first-page":"217","article-title":"Direct oral anticoagulants versus warfarin in patients with left ventricular thrombus","volume":"33","author":"Albabtain","year":"2021","journal-title":"J Saudi Heart Assoc"},{"key":"B28","doi-asserted-by":"publisher","first-page":"884","DOI":"10.21037\/jtd-23-1582","article-title":"Direct oral anticoagulants compared with warfarin in patients with left ventricular thrombus: a cohort study from China","volume":"16","author":"Zhou","year":"2022","journal-title":"J Thorac Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2174\/1570161120666221003104821","article-title":"Efficacy and safety of direct oral anticoagulants in the treatment of left ventricular thrombus after acute anterior myocardial infarction","volume":"20","author":"Liang","year":"2022","journal-title":"Curr Vasc Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40256-022-00533-w","article-title":"Safety and effectiveness of direct oral anticoagulants versus warfarin for treating left ventricular thrombus","volume":"22","author":"Herald","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1465866","DOI":"10.3389\/fcvm.2025.1465866","article-title":"Efficacy and safety of off-label direct oral anticoagulants vs. Warfarin for left ventricular thrombus: an inverse probability of treatment weighting analysis","volume":"12","author":"Al-Maimoony","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.3390\/jcm14062129","article-title":"The efficacy and safety of direct oral anticoagulants compared to warfarin for left ventricular thrombus resolution","volume":"14","author":"Paiva","year":"2025","journal-title":"J Clin Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11239-020-02371-6","article-title":"Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus","volume":"52","author":"Bass","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"B34","first-page":"424","article-title":"Effectiveness of direct oral anticoagulants vs warfarin in patients with left ventricular thrombi","volume":"77","author":"Varwani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/eurheartj\/ehac544.1282","article-title":"Direct oral anticoagulants compared to vitamin K antagonists in patients with left ventricular thrombus","volume":"43","author":"Seiler","year":"2022","journal-title":"Eur Heart J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.amjmed.2024.10.042","article-title":"Comparison of direct oral anticoagulants and vitamin K antagonists for left ventricular thrombus: a global retrospective study","volume":"138","author":"Yao","year":"2025","journal-title":"Am J Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.hrtlng.2025.07.014","article-title":"Direct oral anticoagulants versus vitamin K antagonists for left ventricular thrombus management","volume":"74","author":"Khalid","year":"2025","journal-title":"Heart Lung"},{"key":"B38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.amjcard.2024.11.026","article-title":"Direct oral anticoagulants versus warfarin for the treatment of left ventricular thrombus: a multicenter retrospective observational study","volume":"238","author":"Al-Abcha","year":"2025","journal-title":"Am J Cardiol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1814694\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:33:40Z","timestamp":1778736820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1814694\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":38,"alternative-id":["10.3389\/fcvm.2026.1814694"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1814694","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"article-number":"1814694"}}